Physician profile
Alan J Bell
NPI 1376643478
$27,875.55
in general payments reported to CMS, 2019-2025
69 companies · $5,823 in 2025
The $5,823 reported for 2025 was more than what 86% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,031 · 2020: $1,719 · 2021: $3,027 · 2022: $3,740 · 2023: $4,799 · 2024: $5,737 · 2025: $5,823.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $16K · Education: $204.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $16,155.28 |
| Education | $203.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,741.66 | 2021-2025 | Botox, Qulipta, Ubrelvy |
| Lundbeck LLC | $2,195.94 | 2020-2025 | Vyepti, Rexulti |
| Novartis Pharmaceuticals Corporation | $1,886.92 | 2019-2025 | |
| Biogen, INC. | $1,555.64 | 2019-2025 | Tysabri, Vumerity, Leqembi |
| Mdd US Operations, LLC | $1,178.74 | 2019-2025 | Apokyn, Gocovri, Gocovri |
| Allergan, INC. | $1,085.22 | 2020-2021 | |
| Sk Life Science, INC. | $931.55 | 2020-2025 | Xcopri |
| Pfizer INC. | $922.69 | 2019-2025 | |
| Emd Serono, INC. | $917.10 | 2019-2025 | Mavenclad |
| Amneal Pharmaceuticals LLC | $907.13 | 2019-2025 | Ongentys, Rytary, Crexont |
| Ucb, INC. | $903.34 | 2019-2025 | Briviact, Zilbrysq, Rystiggo |
| Eisai INC. | $888.10 | 2019-2025 | |
| Teva Pharmaceuticals USA, INC. | $825.18 | 2019-2025 | Austedo Xr, Ajovy, Austedo Xr |
| Alexion Pharmaceuticals, INC. | $777.85 | 2019-2025 | Ultomiris, Soliris |
| Genzyme Corporation | $692.31 | 2019-2025 |
Show all 69 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $644.53 | 2019-2025 | Kisunla, Reyvow, Emgality |
| Neurocrine Biosciences, INC. | $639.40 | 2019-2022 | |
| Merz Pharmaceuticals, LLC | $597.68 | 2023-2025 | Xeomin |
| Mallinckrodt Hospital Products INC. | $593.87 | 2022-2025 | Acthar |
| Sunovion Pharmaceuticals INC. | $552.92 | 2019-2022 | |
| Csl Behring | $506.19 | 2019-2025 | Hizentra |
| Ani Pharmaceuticals, INC. | $503.60 | 2023-2025 | Purified Cortrophin Gel |
| Acorda Therapeutics, INC | $378.78 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $336.54 | 2019-2023 | Ponvory |
| Supernus Pharmaceuticals, INC. | $333.78 | 2019-2025 | Qelbree |
| Celgene Corporation | $324.68 | 2022-2025 | Zeposia |
| Amgen INC. | $264.80 | 2021-2025 | Uplizna, Aimovig |
| Biohaven Pharmaceutical Holding Company LTD. | $259.17 | 2022 | |
| Mallinckrodt Enterprises LLC | $257.75 | 2019 | |
| Acadia Pharmaceuticals INC | $244.87 | 2019-2024 | Nuplazid |
| Genentech USA, INC. | $243.76 | 2021-2024 | Ocrevus, Enspryng |
| Neurelis, INC. | $195.69 | 2020-2025 | Valtoco |
| Grifols USA, LLC | $193.50 | 2019-2025 | Gamunex-C |
| Idorsia Pharmaceuticals US INC | $173.26 | 2022-2023 | Quviviq |
| Otsuka America Pharmaceutical, INC. | $160.25 | 2024-2025 | Nuedexta, Rexulti |
| Alnylam Pharmaceuticals INC. | $152.17 | 2023 | Onpattro |
| Impel Pharmaceuticals INC. | $135.37 | 2023 | Trudhesa |
| Takeda Pharmaceuticals U.S.A., INC. | $125.07 | 2021-2025 | Hyqvia |
| Avanir Pharmaceuticals, INC. | $116.91 | 2019-2020 | |
| Ge Healthcare | $116.32 | 2019-2024 | |
| Tanabe Pharma America, INC. | $112.69 | 2023-2025 | Radicava |
| Arbor Pharmaceuticals, INC. | $107.60 | 2019-2021 | |
| Biohaven Pharmaceuticals, INC. | $101.96 | 2020-2021 | |
| Harmony Biosciences LLC | $87.31 | 2025 | |
| Argenx US, INC. | $83.10 | 2022-2025 | Vyvgart Hytrulo |
| Tg Therapeutics, INC. | $79.88 | 2023-2024 | |
| Inspire Medical Systems, INC. | $78.33 | 2024-2025 | Inspire |
| Avion Pharmaceuticals | $66.89 | 2022-2023 | Dhivy |
| Vanda Pharmaceuticals INC. | $58.57 | 2024-2025 | Ponvory |
| Assertio Therapeutics, INC. | $55.00 | 2019 | |
| Life Molecular Imaging LTD | $54.61 | 2024-2025 | Neuraceq |
| E.R. Squibb & Sons, L.L.C. | $47.66 | 2020 | |
| Horizon Therapeutics Plc | $44.59 | 2021-2022 | |
| Zyla Life Sciences, INC. | $42.46 | 2019 | |
| Insightec,INC | $41.74 | 2024-2025 | Exablate |
| Astrazeneca Pharmaceuticals LP | $36.65 | 2023-2025 | Wainua |
| Catalyst Pharmaceuticals, INC. | $34.64 | 2024 | |
| Xeris Pharmaceuticals, INC. | $33.86 | 2025 | Keveyis |
| Globus Medical, INC. | $31.34 | 2025 | Senza |
| Adamas Pharmaceuticals, INC. | $30.92 | 2019-2020 | |
| Axsome Therapeutics, INC. | $30.81 | 2023-2024 | Sunosi |
| Scilex Pharmaceuticals INC. | $24.88 | 2024 | |
| Sanofi-Aventis U.S. LLC | $22.90 | 2020 | |
| Kedrion Biopharma, INC. | $21.13 | 2024 | Kedrab, Albuked, Rhogam Ultra-Filtered Plus |
| Kyowa Kirin, INC. | $20.71 | 2020 | |
| Cycle Pharmaceuticals INC | $19.74 | 2025 | Tascenso Odt, Bafiertam |
| Shire North American Group INC | $15.55 | 2019 | |
| Bausch Health US, LLC | $14.94 | 2022 | |
| Livanova USA, INC. | $14.86 | 2023 | Vns Therapy Sentiva Model 1000 Generator |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alan Bell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.